Transaction DateRecipientSharesTypePriceValue
21st October 2020Joseph S Zakrzewski100,000Exercise of derivative$3.40$340,000.00
9th September 2020Kenneth J. Hillan15,000Grant/award etc.$0.00
24th August 2020Robert Carey10,000Open or private purchase$5.70$57,000.00
14th August 2020Robert Carey10,000Open or private purchase$5.50$55,000.00
14th August 2020Robert Carey50,000Open or private purchase$5.65$282,500.00
13th August 2020Robert Carey5,000Open or private purchase$5.45$27,250.00
13th August 2020Robert Carey5,000Open or private purchase$5.30$26,500.00
25th June 2020David Mark Mc Clung100,000Grant/award etc.$0.00
16th June 2020Stephen George Dilly17,905Grant/award etc.$0.00
11th June 2020Karen L. Smith30,220Grant/award etc.$2.73$82,500.60
Sangamo Therapeutics
Sangamo Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Ticker: SGMO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1001233
Employees: 354
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $467 M (0%)
Assets, Current: $679 M (67%)
Property, Plant and Equipment, Net: $34 M (13%)
Other Assets, Noncurrent: $14 M (52%)
Assets: $895 M (40%)
Liabilities, Current: $94 M (34%)
Other Liabilities, Noncurrent: $6 M (6%)
Liabilities: $383 M (87%)
Common Stock, Value, Issued: $1 M (21%)
Additional Paid in Capital, Common Stock: $1 B (14%)
Retained Earnings (Accumulated Deficit): $736 M (12%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (-32%)
Stockholders' Equity (Parent): $511 M (18%)
Liabilities and Equity: $895 M (40%)
Revenue: $22 M (-37%)
Research and Development: $42 M (-49%)
General and Administrative Expenses: $18 M (-47%)
Operating Income/Loss: $38 M (-54%)